Paediatric anaesthesia
-
Paediatric anaesthesia · Apr 2013
Comparative StudyImpact of rocuronium vs succinylcholine neuromuscular blocking drug choice for laparoscopic pyloromyotomy: is there a difference in time to transport to recovery?
This study evaluates the relationship between neuromuscular blocking drug administered and transport time following laparoscopic pyloromyotomy. ⋯ For laparoscopic pyloromyotomy in term infants using propofol, sevoflurane and no intraoperative opioid, succinylcholine may be the best neuromuscular blocking drug choice, provided no contraindication is present. However, based on the small difference in time to transport, rocuronium as administered herein may be a reasonable alternative preferred by some clinicians.
-
Paediatric anaesthesia · Apr 2013
The characteristics of the staircase phenomenon during the period of twitch stabilization in infants in TOF mode.
Acceleromyography used to monitor the neuromuscular transmission function is available in infants and children. However, information on the so-called staircase phenomenon during the baseline stabilization period in this population is limited. Our objective was to assess the characteristics of such phenomenon in infants in acceleromyography. ⋯ The staircase effect presents in a shorter time course and at lower degrees in smaller infants. However, in older infants, staircase effect still presents in a long period and may influence the onset time and duration of twitch depression after muscle relaxants administration.
-
Paediatric anaesthesia · Apr 2013
Randomized Controlled TrialEffect of short-term propofol administration on pancreatic enzymes and lipid biochemistry in children between 1 month and 36 months.
Use of propofol in pediatric age group has been marred by reports of its adverse effects like hypertriglyceridemia and acute pancreatitis, although a causal relation has not yet been established. ⋯ We conclude that despite a small, transient increase in serum triglycerides and pancreatic enzymes, short-term propofol administration in recommended dosages in children of ASA status I and II aged between 1 month and 36 months does not produce any clinically significant effect on serum lipids and pancreatic enzymes.